—BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan—

BRIDGEWATER, N.J., Oct. 19, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the commercial launch in Japan of BRINSUPRI® Tablets 25 mg (brensocatib hydrate), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older.

"The commercial availability of BRINSUPRI in Japan is a meaningful step forward for the bronchiectasis community and a proud moment for our team," said Samuele Butera, Senior Vice President, General Manager, Global Respiratory for Insmed. "As the first approved therapy specifically designed to address the underlying inflammatory process of NCFB, we are pleased that BRINSUPRI can be made widely available to appropriate patients in Japan who have long needed a treatment option that addresses an unmet driver of their disease."

BRINSUPRI is the first and only approved and commercially available treatment for patients diagnosed with NCFB in Japan. The Japan Ministry of Health, Labour, and Welfare (MHLW) approved BRINSUPRI in August 2026 based on results from the Phase 3 ASPEN study.

"In patients living with bronchiectasis, recurrent exacerbations represent a substantial disease burden, making daily life harder to manage and affecting long-term clinical outcomes," said Makoto Nakamura, Senior Vice President, General Manager, Japan for Insmed. "By offering BRINSUPRI as a new treatment option for appropriate patients in Japan, we hope to contribute to better disease management for eligible patients. Insmed remains committed to supporting the bronchiectasis community through appropriate information provision to healthcare professionals and advancing the proper use of this therapy."

About Bronchiectasis

Bronchiectasis is a serious, chronic lung disease in which the bronchi become permanently dilated due to a cycle of infection, inflammation, and lung tissue damage. The condition is marked by frequent pulmonary exacerbations requiring antibiotic therapy and/or hospitalizations. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections, which can worsen the underlying condition. Most bronchiectasis cases in adults are non-cystic fibrosis bronchiectasis (NCFB).

About BRINSUPRI

BRINSUPRI® (brensocatib) is a small molecule, once-daily, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), designed to inhibit the activation of enzymes (neutrophil serine proteases) in neutrophils that are key drivers of chronic airway inflammation in non-cystic fibrosis bronchiectasis (NCFB). The therapy is approved in the United States as BRINSUPRI (brensocatib 10 mg and 25 mg tablets) and indicated for the treatment of NCFB in adult and pediatric patients 12 years of age or older. In the European Union and United Kingdom, BRINSUPRI (brensocatib 25 mg tablets) is approved for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months. In Japan, BRINSUPRI Tablets 25 mg (brensocatib hydrate) is approved for the treatment of NCFB in adults and pediatric patients 12 years and older.

INDICATION AND IMPORTANT SAFETY INFORMATION FOR BRINSUPRI IN THE U.S.

U.S. Indication

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Important Safety Information

WARNINGS AND PRECAUTIONS

Dermatologic Adverse Reactions

Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings. 

Gingival and Periodontal Adverse Reactions

Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene. 

Live Attenuated Vaccines

It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI. 

ADVERSE REACTIONS

The most common adverse reactions ≥2% in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions. 

Less Common Adverse Reactions

Liver Function Test Elevations

In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of AST >3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline phosphatase >1.5X ULN was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. 

Skin Cancers

In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients. 

Alopecia

In ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10 mg and 25 mg was 1.5% and 1.6%, respectively, compared to 0.4% in placebo-treated patients.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no clinical data on the use of BRINSUPRI in pregnant women. 

Lactation: There is no information regarding the presence of BRINSUPRI and/or its metabolite(s) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BRINSUPRI and any potential adverse effects on the breastfed child from BRINSUPRI or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of BRINSUPRI for the treatment of NCFB have been established in pediatric patients aged 12 years and older. Common adverse reactions in pediatric patients aged 12 years and older enrolled in ASPEN were consistent with those in adults. The safety and effectiveness of BRINSUPRI have not been established in pediatric patients younger than 12 years of age.

Please see full US Prescribing Information.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Forward-looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), may identify forward-looking statements.

The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events, to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: failure to successfully commercialize BRINSUPRI in the U.S., Europe, or Japan, or to maintain U.S.

- Clearance enables initiation of SHIELD-AL, a pivotal study in newly diagnosed patients with lambda AL amyloidosis

- Investigational oral light chain stabilizer to be evaluated as an add-on to standard-of-care plasma cell-directed therapy

SAN DIEGO, Oct. 19, 2026 /PRNewswire/ -- Protego Biopharma, Inc., a clinical-stage biotechnology company developing small molecule therapies for protein misfolding diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PROT-001, enabling the company to initiate SHIELD-AL, its global pivotal Phase 2/3 study, in newly diagnosed light chain (AL) amyloidosis patients. PROT-001 is an oral investigational first-in-class lambda light chain stabilizer for the treatment of AL amyloidosis.

"Improving organ outcomes, particularly cardiac, in AL amyloidosis remains an urgent need, and studies in newly diagnosed patients with cardiac involvement have demonstrated that rapid depletion of amyloidogenic light chains closely correlates to improvements in survival," said Brent J. Warner, MBA, Chief Executive Officer of Protego Biopharma. "This highlights a therapeutic opportunity for PROT-001, which acts directly on amyloidogenic lambda light chains to stabilize and neutralize their toxicity, as a complement to plasma cell-directed therapies that reduce light chain production. SHIELD-AL will evaluate whether this complementary approach with PROT-001 can help patients achieve deeper and faster organ responses while reducing cardiovascular complications beyond standard of care alone."

SHIELD-AL is a randomized, double-blind, placebo-controlled study of PROT-001 in newly diagnosed lambda AL amyloidosis patients, with Part A consisting of an initial safety and dose confirmation study and Part B a pivotal safety and efficacy study.

Protego will be sharing data from its completed Phase 1 study evaluating PROT-001 in healthy volunteers at a medical meeting later this year.

About Protego Biopharma

Protego Biopharma is a clinical-stage biotechnology company developing first-in-class small molecule therapies for AL amyloidosis and other protein misfolding diseases. Protego aims to translate advances in protein stabilization into medicines that address the misfolding and toxicity responsible for progressive organ damage. Its therapies are designed to intervene in this disease process, with the goal of preserving organ function and improving patients' lives. For more information, visit www.protegobio.com.

About PROT-001

PROT-001 is Protego Biopharma's lead investigational small molecule pharmacological chaperone, being developed for the treatment of immunoglobulin light chain (AL) amyloidosis. PROT-001 is designed to stabilize amyloidogenic lambda light chain proteins and prevent their misfolding and the formation of proteotoxic species. The goal of this therapy is limiting the toxic effects that contribute to organ injury, including direct damage to cardiomyocytes in AL patients. PROT-001 represents a complementary approach to plasma cell-directed therapies, which reduce light chain production. By targeting the amyloidogenic light chain protein itself before it can adopt a pathogenic conformation, PROT-001 has the potential to complement existing treatments and address an additional mechanism of disease.

About AL amyloidosis

Immunoglobulin light chain (AL) amyloidosis is a rare, life-threatening disease affecting over 5,100 newly diagnosed patients annually and 28,000 US adults in which abnormal plasma cells produce light chain proteins that can misfold and aggregate. The direct toxicity of disease-related light chains and their accumulation as amyloid deposits in tissues both result in injury to organs, including the heart and kidneys. Cardiac injury is particularly serious, as toxic light chains can directly impair cardiomyocyte function, while amyloid deposits disrupt the structure and function of the heart. Current treatments focus on reducing light chain production with plasma cell-directed therapies and managing organ complications, leaving patients with a substantial need for complementary approaches that directly address light chain toxicity and improve organ outcomes.

SOURCE Protego Biopharma

Share this article

Julia Gillard joins Hakluyt's International Advisory Board

LONDON, Oct. 19, 2026 /PRNewswire/ -- Hakluyt, the global strategic advisory firm for businesses and investors, is delighted to announce the appointment of The Honourable Julia Gillard AC, former prime minister of Australia and current chair of Wellcome, to its international advisory board.

Julia Gillard is one of Australia's most prominent political leaders and an influential figure in global health. She began her career at the law firm Slater & Gordon, where she became a partner, before moving into politics as chief of staff to the premier of Victoria. Elected to the Australian House of Representatives in 1998, Julia served as deputy prime minister from 2007 to 2010, and then as prime minister of Australia from 2010 to 2013 – the first woman to hold the role.

Julia currently serves as chair of Wellcome, the UK-based global charitable foundation focused on improving health through science. She is also patron of the Campaign for Female Education (CAMFED), the inaugural chair of the Global Institute for Women's Leadership at King's College London, and patron of Beyond Blue, a mental health charity in Australia.

Chaired by Lord William Hague, Hakluyt's international advisory board includes senior leaders from across business, government and academia, who support the firm's global connectivity and expertise.

Lord Hague said: "I am delighted to welcome Julia to Hakluyt's international advisory board. She brings first-hand experience of government decision-making that will be of great value to the firm, and her work at Wellcome gives her a global perspective on science, innovation and health, as well as the partnerships needed to tackle some of the world's most pressing challenges."

Julia Gillard commented: "I am excited to be joining Hakluyt's international advisory board. Having had the privilege of serving in public office at the highest level, I have seen how critical sound judgement is in periods of uncertainty and change. I look forward to working with William and my fellow advisory board members to support Hakluyt's clients and the firm's continued growth."

Thomas Ellis, Hakluyt's managing partner, added: "I am thrilled that Julia is joining Hakluyt's international advisory board. She combines exceptional government experience with a deep understanding of the forces shaping economies and societies around the world. As a highly respected voice on leadership questions and many global trends and issues, she brings a distinctive perspective that will strengthen the advice we provide to our clients."

This appointment is effective immediately.

Notes to editors:

Hakluyt is a strategic advisory firm that works with corporate leaders and investors around the world on their most important commercial issues. For more information on the firm, please visit www.hakluytandco.com

SOURCE Hakluyt

Share this article

CME Group Expands Dairy Business with New European Futures and Options

CHICAGO, Oct. 19, 2026 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced plans to launch new European dairy futures and options contracts before the end of 2026, pending all regulatory reviews.

The company will introduce new futures and options contracts for European Skimmed Milk Powder, European Butter, European Whey Powder and European Liquid Milk as a first step toward regional expansion following an agreement with the European Energy Exchange earlier this year.

These products will position CME Group to expand on recent record activity within the Dairy complex, including reaching record monthly open interest of an average 420,922 contracts a day in September, a 42% increase year over year, and an all-time daily open interest record of 461,493 contracts on September 29.

"We've long served the dairy community across the U.S., and now we're bringing that same commitment to Europe," said John Ricci, Global Head of Agricultural Products at CME Group. "By offering futures and options, we're giving participants a more complete toolkit to deploy capital efficiently and manage regional price risk - all on a single platform alongside our U.S. complex."

The new contracts will be financially settled and will initially track EEX indices before transitioning to CME Group indices. They will be listed on and subject to the rules of CME.

CME Group and EEX are also working to transition the EEX Weekly European Cheese Indices and the Pan European Butter Index to CME Group for continued benefit to the industry.

For more information on CME Group's dairy products, please visit here.

As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing.

CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC ("S&P DJI"). "S&P®", "S&P 500®", "SPY®", "SPX®", US 500 and The 500 are trademarks of Standard & Poor's Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners.

CME-G

SOURCE CME Group

Share this article

2026 Canton Fair Design Award Winners Showcase China's Innovation Strength

GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- As the 140th Canton Fair opens, the winners of the 2026 Canton Fair Design Award (CF Award) have also been announced. Winning products are now on display in Area D of the Canton Fair Complex, offering visitors a closer look at some of the latest advances in Chinese manufacturing and industrial design.

Among this year's top honorees, a domestically developed high-performance sport motorcycle and an intelligent navigation capsule robot gastric endoscopy system received the Best of the Best Award, the competition's highest recognition.

The Canton Fair also enhanced the visitor experience with a themed showcase area within the award exhibition. Built around four application-oriented concepts, namely Outdoor Pleasure, Smart Living, Cozy Home and Kitchen Elegance, the immersive displays demonstrate how innovative designs can be integrated into everyday life, helping visitors better understand the practical value behind these award-winning products.

This year, 4,218 products from 2,112 companies competed for the award. Following multiple rounds of evaluation, 222 products from 174 companies were selected.

The award-winning products reflect several key trends shaping the next stage of Chinese manufacturing. Innovation remains a defining theme, with breakthrough technologies ranging from upper limb motor function assistance and enhancement system to exoskeleton robots, underscoring the growing momentum of high-end manufacturing.

Meanwhile, intelligent technologies continue to gain traction across industries. Smart products account for more than 30% of this year's winners, with AI-powered glasses, intelligent conference terminals and smart healthcare devices extending AI applications across home, office, medical and outdoor environments.

Sustainability is also becoming increasingly embedded throughout the product lifecycle. Green products represent over 40% of the winning entries, while innovations such as integrated energy-saving panels and sugarcane paper demonstrate how environmentally conscious practices are being incorporated into product design, materials selection and manufacturing processes.

Established in 2013, the Canton Fair Design Award is widely regarded as a benchmark for design innovation in China's foreign trade sector. The award recognizes products that combine design excellence with commercial value, promoting the transformation and upgrading of Chinese manufacturing and supporting high-quality trade development. Entries are evaluated across five dimensions: innovation, quality, functionality, aesthetics and sustainability.

For more convenient attendance, please click here for pre-registration:

https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

Share this article

Hornbeck Offshore Announces Third Quarter 2026 Earnings Release and Conference Call Schedule

HOUSTON and COVINGTON, La., Oct. 19, 2026 /PRNewswire/ -- Hornbeck Offshore Services, Inc. ("Hornbeck" or the "Company") (NYSE: HOS) today announced that it will release its third quarter 2026 financial results prior to the Company's live conference call, which can be accessed via dial-in or webcast on Thursday, November 5, 2026, at 9:00 a.m. Eastern (8:00 a.m. Central).

For those who cannot listen to the live call, a telephonic replay will be available through November 19, 2026, and may be accessed by calling (201) 612-7415 and using the passcode 13763345#. Also, an archive of the webcast will be available after the call for a period of 60 days at https://ir.hornbeckoffshore.com/news-events/event-calendar on the "Investors" section of the Company's website.

About Hornbeck Offshore Services

Hornbeck is a global offshore services leader, providing innovative and integrated marine and subsea solutions to customers across the deepwater oilfield, defense and renewables industries.

Contacts:

Potter Adams

Executive Vice President and CFO

985-727-6815

[email protected]

Ken Dennard / Alex Harp 

Dennard Lascar Investor Relations 

713-529-6600 

[email protected] 

SOURCE Hornbeck Offshore Services, Inc.

Share this article

Long section view with locations of DKP084 and DKD100, relative to the La Verde porphyry copper-gold discovery2

Step-out drilling has confirmed the discovery of a second porphyry centre – La Verde South - near-doubling the growth potential of the La Verde copper-gold porphyry discovery.

The Company's rapidly emerging cornerstone asset is located 30 km south of its Costa Fuego copper-gold (Cu-Au) Project, located on Chile's coastal range at low elevation.

First step-out Reverse Circulation (RC) drill hole DKP084, located approximately 250 m to the south of La Verde's +0.4% Cu mineralisation footprint, has delivered:

148 m grading 0.44% CuEq1(0.39% Cu, 0.07 g/t Au) from 36 m

Including 44 m grading 0.56% CuEq (0.50% Cu, 0.06 g/t Au) from 138 m

First step-out Diamond (DD) drill hole DKD100, located a further 100 m to the south of DKP084, has visually recorded a 307 m down-hole interval of copper porphyry-style mineralisation3. Diamond drilling is continuing in mineralisation at 347 m and is currently planned to a depth of 500 m.

The maiden La Verde Mineral Resource Estimate (MRE), revised Costa Fuego Pre-Feasibility Study (PFS) and preparation of an Environmental Impact Assessment (EIA) submission all remain on track.

Four drill rigs operating at La Verde, with assay results pending for 25 drill holes (6 southern step-out and 19 resource definition drill holes).

PERTH, Australia, Oct. 19, 2026 /PRNewswire/ -- Hot Chili Limited (ASX: HCH) (TSXV: HCH) (OTCQX: HHLKF) ("Hot Chili" or the "Company") is pleased to announce the discovery of a second porphyry centre at its La Verde Cu-Au deposit (La Verde), located 30 km south of the planned central processing hub for the Company's Costa Fuego Cu-Au Project (Costa Fuego) in Chile's coastal Atacama region.

First step-out drilling has unlocked significant growth potential, with near-surface higher-grade copper mineralisation immediately south of, and along strike, from La Verde.

Christian Easterday, Managing Director of Hot Chili, said:

"We are very pleased with the results of our first step-out drilling to the south of La Verde. Drilling has confirmed a second porphyry centre, concealed beneath shallow Atacama gravels, with the potential to be of similar scale to La Verde.

These initial results provide yet another boost to Hot Chili's growth plans for its Costa Fuego copper hub in Chile.

Costa Fuego is already one of the top five independent copper developments by scale. The upcoming addition of a maiden MRE for La Verde, and now confirmation of a much larger discovery than first recognised, is a game changer for the Company."

First RC Step-out Drilling Delivers Broad Extension of Shallow Oxide Footprint

Step-out drill hole DKP084 was collared along strike, approximately 250 m south of La Verde's existing +0.4% Cu mineralisation footprint, which has been defined by over 40,000 m of RC and DD drilling to date. DKP084 returned a significant intersection of 148 m grading 0.44% CuEq (0.39% Cu, 0.07 g/t Au) from 36 m, including 44 m grading 0.56% CuEq (0.50% Cu, 0.06 g/t Au) from 138 m.

DKP084 was designed to follow-up and test for extensions south of previously reported RC drill hole DKP024, which recorded 114 m grading 0.4% CuEq (0.4% Cu) from 86 m, including 52 m grading 0.5% CuEq (0.5% Cu, 0.1 g/t Au) from 96 m (see announcement dated 19 May 2025).

The intersection in DKP084 is primarily oxide copper porphyry-style mineralisation, commencing immediately below shallow gravel cover.

First DD Step-out Drill Hole Confirms Second Porphyry Centre at La Verde South

Building on the initial RC drill results from DKP024 and DKP084, Hot Chili mobilised a diamond drill rig to test the potential for higher-grade copper porphyry-style sulphide mineralisation below the wide zone of oxide mineralisation.

Diamond drill hole DKD100 was collared a further 100 m to the south of DKP084, and like DKP084, has visually recorded a wide zone of copper porphyry-style oxide mineralisation (associated with copper clays, malachite and black copper oxide mineralogy) between 40 m and 172 m down hole depth.

Significantly, below this oxide zone, DKD100 has also visually recorded a wide zone of porphyry-style sulphide mineralisation (associated with disseminated chalcopyrite and porphyry-style A, B and C veining) between 172 m and 347 m down hole depth (current depth of hole). DKD100 is continuing and currently planned to a depth of 500 m.

Drilling is continuing with two drill rigs (one DD and one RC) testing La Verde South, while the remaining two drill rigs (one DD and one RC) continue infill drilling La Verde ahead of the Company's planned completion of a maiden MRE.

Core photo from DKD100 (259 – 261 m downhole) with vein-hosted and disseminated chalcopyrite and pyrite mineralisation in strongly veined tonalite host rock1

Further drill results are expected to be released shortly from La Verde and the newly discovered La Verde South porphyry centre.

This announcement is authorised by the Board of Directors for release to ASX and TSXV.

Figure 1. Location of La Verde in relation to Costa Fuego, coastal range Chile

Table 1. New significant drilling intersections from La Verde

Table 2. Mineral abundance details for DKD100

Figure 2. Plan view map of La Verde showing recent drill hole result and +0.2% copper (yellow), +0.3% copper (red), +0.4% copper (magenta) mineralisation interpolants prior to inclusion of DKP084. Drilled holes with pending assays are shown in black. Position of A – A' long section (front page figure) annotated with white dashed lines. Conceptual open pit shells1 displayed for $US3.50/lb Cu (short dash) and $US6.00/lb Cu (long dash) displayed as dashed lines. Returned Cu grades shown on traces, results reported including CuEq2, visual estimate from DKD100 shown3.

Figure 3. Plan view slice at 950 mRL (+- 150 m) with La Verde showing geological model. Collar locations for existing drillholes (black outline where assays have been received, red outline where assays are pending) and planned drillholes (blue outline) are included. Conceptual open pit shells1 displayed for $US3.50/lb Cu (short dash) and $US6.00/lb Cu (long dash) displayed as dashed lines. Returned Cu grades shown on traces, results reported including CuEq2, visual estimate from DKD100 shown3.

Qualifying Statements

Conceptual Open Pit Shells

Conceptual open pit shells represent Exploration Targets as defined in the 2012 Edition of the 'Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves' (JORC Code). They are based on completed exploration activities reported in the announcement released 19 May 2025 ('Hot Chili Announces Latest Drill Results for La Verde, Doubling Porphyry Discovery Footprint').

The conceptual open pit shells were generated using copper (Cu) prices of US$3.50/lb Cu and US$6.00/lb Cu on a series of nested Cu grade shells. Other input parameters informing the conceptual open-pit shells (pit slope angles, mining cost, processing cost, etc.) were derived from values reported in the March 2025 Costa Fuego Pre-Feasibility Study and are considered appropriate for the style of mineralisation encountered at the La Verde Cu-Au porphyry discovery.

Any potential quantity and grade of the Exploration Target shown is conceptual in nature. There has been insufficient exploration to estimate a Mineral Resource within the target area, and it is uncertain if further exploration will result in the estimation of a Mineral Resource.

Further exploration activities are detailed in this announcement and include (but may not necessarily be limited to) a program of diamond drillholes aiming to extend the mineralised footprint at La Verde. Drilling commenced on 22 September 2025, with the length of the program dependent on a number of considerations including (but not limited to) the results of the exploration activities and regulatory applications and approvals.

Qualified Person – NI 43-101

The technical information in this announcement has been reviewed and approved by Mr Christian Easterday, MAIG, Hot Chili's Managing Director and a qualified person within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects. For further information, please refer to the Company's technical report titled "Costa Fuego Project, NI 43-101 Technical Report Preliminary Feasibility Study", with an effective date of 27 March 2025, a copy of which is available for review under the Company's issuer profile on SEDAR+ (www.sedarplus.ca).

Competent Person – JORC

The information in this announcement that relates to Exploration Results and Exploration Targets for the La Verde project is based upon information compiled by Mr Christian Easterday, the Managing Director and a full-time employee of Hot Chili Limited, who is a Member of the Australasian Institute of Geoscientists (AIG). Mr Easterday has sufficient experience that is relevant to the style of mineralisation and type of deposits under consideration and to the activity which he is undertaking to qualify as a 'Competent Person' as defined in the 2012 Edition of the 'Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves' (JORC Code). Mr Easterday consents to the inclusion in this announcement of the matters based on their information in the form and context in which it appears.

Discoveries Today Examines How Innovation Is Expanding Access, Strengthening Security, and Transforming Business Operations.

Tune in to Bloomberg Television on Saturday, October 24, 2026, at 8:00 p.m. ET.

JUPITER, Fla., Oct. 19, 2026 /PRNewswire/ -- Discoveries Today , the nationally televised educational series hosted by Daymond John, will explore how innovation is shaping modern society in an upcoming episode.

The episode begins by examining the evolving approach to supporting people with intellectual and developmental disabilities. Audiences will learn about the essential role of direct support professionals, the challenges of recruiting and retaining qualified staff, and the importance of vocational training, life-skills development, and inclusive community programs. The segment will highlight how assistive technologies can help individuals communicate more effectively, build confidence, and exercise greater independence. It will also explore how by focusing on practical support and individual choice, communities can create opportunities for people of all abilities to lead more fulfilling lives.

Next, learn about zero-trust security, operational technology protection, and the importance of verifying AI identities, permissions, and actions before they can affect sensitive systems. The discussion shares how AI governance is being designed for critical infrastructure and regulated environments, while exploring how AI governance software is being aligned with federal security requirements and frameworks. The segment also emphasizes the importance of accountability, verifiable decision-making, and security measures to help organizations maintain control over increasingly autonomous technologies.

Discoveries Today will also look at how digital technology is reshaping the automotive retail experience. With consumers increasingly researching vehicles online before visiting a dealership, maintaining an active and accurate digital presence has become an important part of attracting prospective buyers and building customer trust. Viewers will see how AI-powered inventory marketing can help dealerships generate and update content as vehicles are added, modified, or sold, and how by combining automation with consistent digital marketing practices, dealerships can reduce administrative demands, while dedicating more time to customer relationships and to the buying experience.

To close, the show will educate about the growing need for accessible and effective behavioral healthcare and will examines some of the barriers that can prevent people from receiving appropriate treatment and care. The segment will explore the development of more integrated outpatient approaches that combine psychoeducation, therapy, medication management, group support, and family involvement. The discussion will look at how coordinated care and immersive therapeutic environments may provide more continuous and personalized support for adults experiencing mental health and substance-use challenges.

"Each segment offers an educational perspective on the technologies, strategies, and people working to improve accessibility, strengthen security, and create more efficient business practices. Together, these stories demonstrate how thoughtful innovation can translate emerging capabilities into practical, real-world impact,"  said Dustin Schwarz, programming director for Discoveries Today.

About Discoveries Today:

Discoveries Today is a nationally televised, information-based educational television series dedicated to exploring the latest advances taking place across several industries and economies. The program goes behind the scenes to showcase the people, ideas, and breakthroughs contributing to global progress today. The award-winning producers and creative team behind Discoveries Today remain dedicated to sharing how technology and innovation are working together to drive the world forward.

For more information, please visit www.DiscoveriesToday.com or call 866-992-0665.

SOURCE Discoveries Today

Share this article

LONDON, Oct. 19, 2026 /PRNewswire/ -- Brightstar Lottery PLC (NYSE: BRSL) ("Brightstar") will host a conference call and live webcast on Tuesday, November 10, to discuss third quarter 2026 results for the period ended September 30, 2026.

Conference call details:

Tuesday, November 10, 2026

8:00 a.m. EST

Conference call registration: Participants are encouraged to pre-register for the conference call by clicking here. Upon registering, participants will receive a dial-in number and unique PIN.

Webcast registration: A live, listen-only webcast is available under "Events and Presentations" on Brightstar's Investor Relations website at ir.brightstarlottery.com. A replay will also be available on the website following the call.

About Brightstar Lottery PLC

Brightstar Lottery PLC (NYSE: BRSL) is a global leader in lottery focused on innovation and forward-thinking strategies and solutions, building on our renowned expertise in delivering secure technology and producing reliable, comprehensive solutions for our customers. As a premier pure play global lottery company, our best-in-class lottery operations, retail and digital solutions, and award-winning lottery games enable our customers to achieve their goals, entertain players and distribute meaningful benefits to communities. Brightstar has a well-established local presence and is a trusted partner to governments and regulators around the world, creating value by adhering to the highest standards of service, integrity, and responsibility. Brightstar serves nearly 90 lottery customers and their players on six continents. It is the primary technology provider to 26 of the 46 lottery jurisdictions in the U.S. and eight of the world's 10 largest lotteries with central systems. Brightstar has approximately 6,000 employees. For more information, please visit www.brightstarlottery.com or follow along on LinkedIn.

Contact:

Mike DeAngelis, Corporate Communications, +1 (401) 392-1000,

[email protected]

Matteo Selva, Italian media inquiries, +39 366 6803635

James Hurley, Investor Relations, +1 (401) 392-7190

© 2026 Brightstar Lottery PLC

The trademarks and/or service marks used herein are either trademarks or registered trademarks of Brightstar Lottery PLC, its affiliates or its licensors.

SOURCE Brightstar Lottery PLC

Share this article

BOSTON, Oct. 19, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) will release its fiscal 2026 fourth quarter and full year results on Wednesday, November 4th after the stock market closes. As previously announced on October 5th, 2026, PTC entered into a definitive agreement to be acquired by Schneider Electric. In light of the pending transaction, PTC is suspending quarterly earnings conference calls and is no longer providing quarterly or annual guidance.

The earnings press release and accompanying financial data tables will be accessible on the Investor Relations section of the company's website at PTC Investor Relations.

About

PTC (NASDAQ: PTC) is a global software company that enables manufacturers and product companies to digitally transform how they design, manufacture, and service the physical products the world relies on. Headquartered in Boston, Massachusetts, PTC employs over 7,000 people and supports more than 30,000 customers globally. For more information, please visit www.ptc.com.

Investors

Michael Maguire

[email protected]

[email protected]

SOURCE PTC Inc.

Share this article